GuidelineThe journal of nutrition, health & aging2013
Designing pharmaceutical trials for sarcopenia in frail older adults: EU/US Task Force recommendations.
Guideline in The journal of nutrition, health & aging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Trial
- Examining Factors Associated with Dynapenia/Sarcopenia in Patients with Schizophrenia: A Pilot Case-Control Study.Healthcare (Basel, Switzerland) · 2023Article
- The Relevance in the Neutrophil to Lymphocyte Ratio and the SARC-F Score in Gastrointestinal Diseases.Journal of clinical medicine · 2022Article
- Skeletal muscle extracellular matrix remodeling with worsening glycemic control in nonhuman primates.American journal of physiology. Regulatory, integrative and comparative physiology · 2021Article
- Critical appraisal of papers reporting recommendation on sarcopenia using the AGREE II tool: a EuroAIM initiative.European journal of clinical nutrition · 2020Article
- Clinically Meaningful Change for Physical Performance: Perspectives of the ICFSR Task Force.The Journal of frailty & aging · 2020Article
- ICFSR Task Force Perspective on Biomarkers for Sarcopenia and Frailty.The Journal of frailty & aging · 2020Article
- Inducible Rpt3, a Proteasome Component, Knockout in Adult Skeletal Muscle Results in Muscle Atrophy.Frontiers in cell and developmental biology · 2020Article
- Development of Pharmacotherapies for the Treatment of Sarcopenia.The Journal of frailty & aging · 2019Review
- Does sarcopenia predict change in mobility after hip fracture? a multicenter observational study with one-year follow-up.BMC geriatrics · 2018Observational
- Public Health issues in hospital management of Sarcopenic patients.Journal of frailty, sarcopenia and falls · 2017Review
- Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia.Aging clinical and experimental research · 2016Review
- Muscle quality in aging: a multi-dimensional approach to muscle functioning with applications for treatment.Sports medicine (Auckland, N.Z.) · 2015Review
- Community-dwelling female fallers have lower muscle density in their lower legs than non-fallers: evidence from the Saskatoon Canadian Multicentre Osteoporosis Study (CaMos) cohort.The journal of nutrition, health & aging · 2015Article
- Proteasome dysfunction induces muscle growth defects and protein aggregation.Journal of cell science · 2014Article
- The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.The journal of prevention of Alzheimer's disease · 2014Article
- Article
- Representation of older patients in clinical trials for drug approval in Japan.The journal of nutrition, health & aging · 2014Article
- Intramuscular fat and inflammation differ in older adults: the impact of frailty and inactivity.The journal of nutrition, health & aging · 2014Article
- From sarcopenia to frailty: a road less traveled.Journal of cachexia, sarcopenia and muscle · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 14 institutions in 4 countries.
Funding
Abstract
An international task force of academic and industry leaders in sarcopenia research met on December 5, 2012 in Orlando, Florida to develop guidelines for designing and executing randomized clinical trials of sarcopenia treatments. The Task Force reviewed results from previous trials in related disease areas to extract lessons relevant to future sarcopenia trials, including practical issues regarding the design and conduct of trials in elderly populations, the definition of appropriate target populations, and the selection of screening tools, outcome measures, and biomarkers. They discussed regulatory issues, the challenges posed by trials of different types of interventions, and the need for standardization and harmonization. The Task Force concluded with recommendations for advancing the field toward better clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.